



## NUMERAL LTD

(Incorporated in the Republic of Mauritius)  
(Registration number: 098177 C1/GBL)  
Primary Listing SEM share code: NXII.N0000.  
Secondary Listing JSE share code: XII  
ISIN: MU0330N00004  
("the Company" or "the Group" or "Numeral")

---

### UPDATE ON HEALTHCARE AND BIOTECH STRATEGY, INVESTMENTS AND THE FINALISATION OF AUDITED RESULTS

---

Shareholders are provided with the following updates as follows:

#### **Update on healthcare and biotech segment:**

1. The Board is pleased to announce that Numeral has expanded its healthcare and biotechnology strategy through a number of strategic initiatives across the premium wellness, sports recovery and healthcare sectors.

During the period, the Group launched Boost & Recovery, a premium longevity, sports wellness and recovery concept designed to deliver science-backed recovery, performance optimisation and preventative healthcare services.

The first flagship facility is currently under development at Kyalami, with completion expected within the next 60 days. Additional flagship locations are planned for Sandton City and Camps Bay, forming part of a broader national rollout strategy.

Each centre will offer an integrated range of advanced recovery and longevity treatments, including whole-body cryotherapy, hyperbaric oxygen therapy, HOCATT ozone therapy, red light therapy, clinical diagnostics and other evidence-based recovery technologies designed to optimise health, wellness and athletic performance.

2. The Board is further pleased to announce that Numeral has made its first strategic investment into WestMed, an established healthcare platform based in Stellenbosch in the Western Cape.

WestMed operates primary healthcare clinics, specialist medical practices, aesthetic medicine, advanced surgical services and regenerative medicine capabilities. The investment aligns with Numeral's long-term strategy of building a leading healthcare, health technology and biotechnology platform.

Further details regarding this investment will be announced in due course.

3. The Board has decided to exit its investments in Longevity and Isopharm due to the inability to secure timely operational and financial information from the founder for purposes of consolidation. The Board has thus determined that it does not have control as envisaged in IFRS 10, nor significant influence in terms of IAS 28, and has accounted for the two companies as investments in its results for the year ended 28 February 2026.

Management decided to enter into a settlement agreement with the founder subsequent to year end to recover its investments as opposed to forcing operational control on the founder and potentially destroying the underlying businesses. This fact has been disclosed in the Annual Financial Statements for February 2026.

4. The shareholding in Cryo-Save was increased to 51% during the year ended 28 February 2026 as expected. Cryo-Save continues to operate well and is enjoying solid growth, being a cornerstone of the biotech business.

**Update on finalisation of Annual Financial Statements for the year ended 28 February 2026:**

The audited results are targeted to be finalised on or about 15 July 2026. The accounting treatment of the two investments in Longevity and Isopharm has been one of the major delaying factors.

Following the decision to exit the investments at cost as detailed above, the accounting treatment can be finalised and the audit for the year ended 28 February 2026 completed.

*Numeral has its primary listing on the Stock Exchange Mauritius and a secondary listing on the AltX of the JSE.*

**By Order of the Board**

9 July 2026

<b>Executive Directors:</b> Dave van Niekerk Neville Graham Jacobus Botma	<b>Non-Executive Directors:</b> Mohamed Yusuf Sooklall Dr Aansa Devi Bedacee Kevin Evans
<b>JSE Sponsor:</b> AcaciaCap Advisors Proprietary Limited	<b>Management Company and Company Secretary:</b> LTS Management Services Limited